Erastin: Benchmark Ferroptosis Inducer for Cancer Biology & Ferroptosis Research

Executive Summary: Erastin (CAS 571203-78-6) is a chemically defined small molecule that induces ferroptosis, a form of iron-dependent, non-apoptotic cell death, by inhibiting the cystine/glutamate antiporter system Xc⁻ and modulating VDAC activity (APExBIO; Chen et al., 2024). It is highly selective for tumor cells with oncogenic RAS (HRAS/KRAS) or BRAF mutations. Erastin is insoluble in water and ethanol but is soluble in DMSO at ≥10.92 mg/mL with gentle warming; it is unstable in solution and recommended for fresh preparation. The compound enables robust, reproducible induction of ferroptosis in engineered human tumor cells or HT-1080 fibrosarcoma cells, supporting cancer biology and oxidative stress research. Evidence from peer-reviewed studies highlights its precision, mechanism, and translational relevance for redox biology and therapy resistance research.

Biological Rationale

Ferroptosis is a regulated cell death mechanism distinct from apoptosis and necrosis. It is characterized by iron-dependent lipid peroxidation and accumulation of reactive oxygen species (ROS), leading to plasma membrane damage. Tumor cells with aberrant redox metabolism, particularly those harboring RAS or BRAF mutations, are especially vulnerable to ferroptosis. Oxidative lipid damage and glutathione depletion are central features of this pathway (Chen et al., 2024). Chemical inducers such as Erastin offer precise control for probing ferroptosis in cell culture and animal models. Recent studies implicate ferroptosis in cancer therapy response, atherosclerosis, and resistance mechanisms (Chen et al., 2024).

Mechanism of Action of Erastin

Erastin, developed and distributed by APExBIO (product page), acts by two principal mechanisms:

• System Xc⁻ Inhibition: Erastin blocks the cystine/glutamate antiporter (system Xc⁻), reducing cystine import and depleting intracellular glutathione (GSH) stores. This loss impairs glutathione peroxidase 4 (GPX4) activity, resulting in unchecked lipid ROS and ferroptotic cell death (Chen et al., 2024).
• VDAC Modulation: Erastin interacts with the voltage-dependent anion channel (VDAC) in the mitochondria, disrupting redox homeostasis and exacerbating ROS accumulation.

These mechanisms converge to induce ferroptosis, particularly in cells with RAS-RAF pathway activation. Notably, ferroptosis is caspase-independent and morphologically distinct from apoptosis (Chen et al., 2024).

Evidence & Benchmarks

• Erastin induces iron-dependent, non-apoptotic cell death in RAS-mutant and BRAF-mutant tumor cells via system Xc⁻ inhibition (APExBIO).
• Erastin treatment (10 μM, 24 h) in HT-1080 fibrosarcoma cells robustly triggers ferroptosis, characterized by increased lipid peroxidation and ROS generation (Chen et al., 2024).
• Ferroptosis is distinct from apoptosis: Erastin-induced cell death is not prevented by caspase inhibitors but is blocked by ferrostatin-1, a ferroptosis inhibitor (Chen et al., 2024).
• Erastin’s specificity for RAS- and BRAF-mutant cells enables selective targeting of cancer cell populations, minimizing off-target effects in wild-type cells (APExBIO).
• Depletion of intracellular glutathione and suppression of GPX4 activity by Erastin are hallmarks of its mechanism (Chen et al., 2024).
• Pharmacological induction of ferroptosis using Erastin is a validated model for studying redox vulnerabilities and resistance in cancer biology (Erastin: Precision Ferroptosis Inducer—this article details actionable workflows; the current article provides updated evidence and mechanistic clarity).

Applications, Limits & Misconceptions

Erastin is a gold-standard research tool for:

• Ferroptosis pathway dissection in cancer biology and therapy resistance studies.
• Oxidative stress assays in engineered cell lines, especially RAS- or BRAF-mutant models.
• Preclinical screens for drugs modulating redox homeostasis or ferroptosis sensitivity.
• Modeling iron-dependent cell death in cardiovascular and neurodegenerative research.

Compared to related work (Harnessing Ferroptosis), which explores translational strategies, this article details Erastin's chemical benchmarks and mechanistic evidence relevant for protocol optimization.

Common Pitfalls or Misconceptions

• Erastin does not induce apoptosis or necrosis; its effect is iron- and ROS-dependent and caspase-independent (Chen et al., 2024).
• It is not effective in cell lines lacking system Xc⁻ expression or with wild-type RAS/BRAF status.
• Erastin is unstable in solution; fresh preparations are required for reproducible results (APExBIO).
• Solubility is limited to DMSO (≥10.92 mg/mL); it is insoluble in water and ethanol.
• Ferrostatin-1 or similar ferroptosis inhibitors will abrogate Erastin's effect, serving as critical negative controls.

Workflow Integration & Parameters

For experimental reproducibility and optimal results:

• Use Erastin at 10 μM for 24 hours in HT-1080 or engineered tumor cells to induce ferroptosis (APExBIO).
• Prepare stock solutions at ≥10.92 mg/mL in DMSO with gentle warming; store aliquots at -20°C for up to several months.
• Freshly dilute stocks into assay buffer immediately before use to minimize degradation.
• Monitor endpoints: lipid ROS (e.g., C11-BODIPY), glutathione levels, cell viability, and iron accumulation.
• Include ferroptosis inhibitors (ferrostatin-1) as controls to confirm specificity.

The Erastin B1524 kit from APExBIO is shipped with blue ice and should be stored at -20°C.

This article extends scenario-based guidance from Erastin: Scenario-Driven Solutions by providing updated evidence and mechanistic detail for practitioners seeking high data integrity.

Conclusion & Outlook

Erastin is a validated, mechanistically precise ferroptosis inducer supporting cancer biology, oxidative stress, and ferroptosis research. It enables targeted studies of iron-dependent, non-apoptotic cell death, especially in RAS- or BRAF-mutant tumor models. As new evidence emerges for ferroptosis in disease and therapy, Erastin will remain a benchmark activator for dissecting redox vulnerabilities and advancing translational workflows. APExBIO provides Erastin (B1524) with quality assurance for research applications. For further scenario-driven protocol advice, see the related scenario analysis article, which addresses reproducibility and assay optimization; the present article offers mechanistic and benchmark-focused updates.